Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pediatric Endocrinology

Treatment and Daily Management

At a Glance

For children with hypoinsulinemic hypoglycemia and body hemihypertrophy, daily care focuses on steady carbohydrate delivery through scheduled feeds, uncooked cornstarch, or sometimes overnight tube feeding. CGMs show trends but do not replace rescue treatment or emergency care.

Managing a condition where the insulin signaling pathway is inappropriately activated requires a specialized approach. Unlike common forms of diabetes or even traditional hyperinsulinism, the goal here is to provide a constant source of energy to a body that is continuously “vacuuming up” sugar from the blood [1][2].

Because the problem is often inside the cells and not caused by too much insulin in the blood, traditional treatments often fail, making nutritional and targeted strategies the mainstays of care [1][3].

Nutritional Foundations: The First Line of Defense

The primary goal is euglycemia—maintaining blood sugar in a normal, safe range. This is often achieved through a combination of strategies prescribed by a specialist. Do not start or change cornstarch or tube-feed rates without the metabolic/endocrine dietitian’s plan.

  • Frequent Carbohydrate Feedings: Shortening the time between meals ensures a steady supply of glucose [2][4].
  • Uncooked Cornstarch: This provides a steady “trickle” of sugar into the bloodstream over several hours [5]. It has age-, dose-, preparation-, and gastrointestinal-related considerations [2].
  • Nocturnal Enteral Feeding: Some children may require feeding through a tube (NG or G-tube) while they sleep [2][4]. This carries pump and tube-displacement contingencies [6].

Why Traditional Medications Often Fail

In many cases of low blood sugar, doctors use a medication called diazoxide. Diazoxide works by telling the pancreas to stop releasing insulin [7].

However, in your child’s case, the pancreas may already be releasing very little insulin. Therefore, diazoxide is generally ineffective for pseudohyperinsulinism because there is no excess insulin for it to suppress [3][8].

Targeted Therapies

Because we now understand the specific genetic pathways involved, doctors are beginning to use medications that target the pathway directly. These are often used “off-label”, evidence for correcting hypoglycemia is limited to selected reports, and they should only be managed by expert centers.

  • Alpelisib (for PIK3CA-related): In small studies, children with PIK3CA mutations and severe hypoglycemia were able to reduce tube feedings after several months [4]. Note that alpelisib can cause hyperglycemia, colitis (inflammation of the colon), mouth sores (stomatitis), and skin rashes [4][9].
  • Sirolimus (for AKT2-related): Case reports have shown it can help normalize blood sugar [10][6]. Sirolimus is not an established treatment for every AKT2 variant and requires monitoring of drug levels, blood counts, renal function, lipids, and infection risk [11].

The Role of Technology: CGMs vs. Fingersticks

Continuous Glucose Monitors (CGMs)—sensors that sit on the skin and track sugar trends—are invaluable for seeing where a child’s sugar is heading. In some pediatric cohorts, they provided predictive alerts that saved families an average of 21 minutes of hypoglycemia time per day [12].

However, CGMs are an adjunct rather than a diagnostic or emergency-treatment device. Such estimates are device-, age-, and population-dependent. In some studies, they caught only 40% to 56% of actual low sugar events and issued many false alarms [13][12].

A fingerstick can confirm a questionable or asymptomatic CGM reading when this does not delay treatment, but it must never delay rescue glucose, prescribed glucagon, or emergency care [14][15].

Preparing for the Long Term

As children grow, their sugar needs often change. Some families see an improvement in symptoms as the child gets older, though this varies significantly by the specific genetic cause [16]. Regular follow-ups with a pediatric metabolic or endocrine specialist are essential.

Common questions in this guide

What is the main daily treatment for hypoinsulinemic hypoglycemia?
The goal is to keep blood sugar in a safe, normal range by providing glucose regularly. A specialist may prescribe frequent carbohydrate feeds, uncooked cornstarch, or overnight tube feeding, depending on the child’s needs.
How is uncooked cornstarch used to prevent low blood sugar?
Uncooked cornstarch releases glucose gradually over several hours and may be included in a specialist-designed feeding plan. The dose, preparation, timing, and monitoring depend on the child’s age, gastrointestinal tolerance, and response, so families should not change it without their metabolic or endocrine dietitian.
Why is diazoxide usually not effective for this type of low blood sugar?
Diazoxide lowers blood sugar by telling the pancreas to release less insulin. In hypoinsulinemic hypoglycemia, insulin may already be low, so there may be little excess insulin for diazoxide to suppress.
Could alpelisib or sirolimus help my child?
These medicines may be considered by expert centers for selected PIK3CA-related or AKT2-related cases, but evidence is limited and use is often off-label. Alpelisib can cause high blood sugar, colitis, mouth sores, and rash, while sirolimus requires monitoring for drug levels, blood counts, kidney function, lipids, and infections.
Can a CGM be trusted to detect every low blood sugar event?
A CGM is useful for showing glucose trends and sending alerts, but it can miss some low readings and produce false alarms. If a reading is unclear, a fingerstick can help when it will not delay rescue glucose, prescribed glucagon, or emergency care.
What should we do if our child vomits or has persistent low blood sugar?
Follow the emergency plan provided by your child’s metabolic or endocrine team, including the instructions for rescue glucose or prescribed glucagon. Seek emergency care when directed, and do not delay treatment while waiting for a CGM reading or fingerstick.
Can this condition get better as a child grows?
Some families notice fewer symptoms as their child gets older, but the course varies substantially with the genetic cause. Ongoing follow-up is important because feeding needs, safe fasting intervals, and monitoring plans can change over time.

Get notified when new evidence is published on Hypoinsulinemic hypoglycemia and body hemihypertrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    An expanded clinical spectrum of hypoinsulinaemic hypoketotic hypoglycaemia.

    Welters A, Leiter SM, Bachmann N, et al.

    Orphanet journal of rare diseases 2023; (18(1)):360 doi:10.1186/s13023-023-02954-5.

    PMID: 37974153
  2. 2

    Treatment of hypoglycemia due to a rare pathogenic variant in AKT2 with waxy maize heat-modified starch.

    Parker M, Yau D

    Clinical case reports 2024; (12(2)):e8473 doi:10.1002/ccr3.8473.

    PMID: 38344362
  3. 3

    Facial Dysmorphic Features in a Patient With Nonketotic Hypoglycemia and a Pathogenic Variant in the AKT2 Gene.

    Ochoa Molina MF, Poggi H, De Toro V, et al.

    AACE clinical case reports 2022; (8(3)):109-112 doi:10.1016/j.aace.2021.11.006.

    PMID: 35602880
  4. 4

    Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With PIK3CA-Related Overgrowth Spectrum.

    Nasomyont N, Rutter MM, Backeljauw PF

    JCEM case reports 2023; (1(2)):luad027 doi:10.1210/jcemcr/luad027.

    PMID: 37908459
  5. 5

    Hypoinsulinemic hypoglycemia with hemihypertrophy in a Filipino infant: management in a resource-limited setting.

    Perez EGM, Estrada SC

    JCEM case reports 2026; (4(11)):luag231 doi:10.1210/jcemcr/luag231.

    PMID: 42871118
  6. 6

    Efficacy and safety of sirolimus therapy in familial hypoinsulinemic hypoglycemia caused by AKT2 mutation inherited from the mosaic father.

    Dushar M, Nowaczyk J, Pyrżak B, et al.

    European journal of medical genetics 2021; (64(12)):104368 doi:10.1016/j.ejmg.2021.104368.

    PMID: 34673243
  7. 7

    Hyperinsulinemic Hypoglycemia in a Patient With a Mutation in the Insulin Receptor.

    Imamovic M, Vågberg M, Cederquist K, Dahlqvist P

    JCEM case reports 2024; (2(12)):luae221 doi:10.1210/jcemcr/luae221.

    PMID: 39659391
  8. 8

    Autocrine insulin increases plasma membrane K(ATP) channel via PI3K-VAMP2 pathway in MIN6 cells.

    Xu S, Kim JH, Hwang KH, et al.

    Biochemical and biophysical research communications 2015; (468(4)):752-7.

    PMID: 26585489
  9. 9

    FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.

    Singh S, Bradford D, Li X, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(1)):23-28 doi:10.1158/1078-0432.CCR-23-1270.

    PMID: 37624421
  10. 10

    The Effectiveness of Sirolimus Treatment in Two Rare Disorders with Nonketotic Hypoinsulinemic Hypoglycemia: The Role of mTOR Pathway

    Şıklar Z, Çetin T, Çakar N, Berberoğlu M

    Journal of clinical research in pediatric endocrinology 2020; (12(4)):439-443 doi:10.4274/jcrpe.galenos.2020.2019.0084.

    PMID: 32157856
  11. 11

    Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.

    Parker VER, Keppler-Noreuil KM, Faivre L, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(5)):1189-1198 doi:10.1038/s41436-018-0297-9.

    PMID: 30270358
  12. 12

    Inpatient continuous glucose monitoring halves the risk of hypoglycemia in patients with hyperinsulinism.

    Chandra C, De Silva S, Worthington S, et al.

    Frontiers in endocrinology 2026; (17()):1943475 doi:10.3389/fendo.2026.1943475.

    PMID: 42959150
  13. 13

    Continuous Glucose Monitoring-Derived Glycemic Phenotyping of Childhood Hypoglycemia Due to Hyperinsulinism: A Year-long Prospective Nationwide Observational Study.

    Worth C, Auckburally S, Worthington S, et al.

    Journal of diabetes science and technology 2025; (19(6)):1528-1537 doi:10.1177/19322968241255842.

    PMID: 39564699
  14. 14

    Recommendations on the Collection of Comparator Measurement Data in the Performance Evaluation of Continuous Glucose Monitoring Systems.

    Freckmann G, Pleus S, Eichenlaub M, et al.

    Journal of diabetes science and technology 2025; (19(4)):1072-1081 doi:10.1177/19322968251336221.

    PMID: 40326433
  15. 15

    The utility of continuous glucose monitoring systems in the management of children with persistent hypoglycaemia.

    Vijayanand S, Stevenson PG, Grant M, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(12)):1567-1572 doi:10.1515/jpem-2021-0414.

    PMID: 34520640
  16. 16

    Constitutive Activation of AKT2 in Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic Dyslipidemia.

    Minic M, Rocha N, Harris J, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(8)):2914-2921 doi:10.1210/jc.2017-00768.

    PMID: 28541532

This page is for informational purposes only and does not constitute medical advice. Your child’s metabolic or endocrine team should individualize feeding, glucose rescue, monitoring, and any targeted medicines.

Guide contents Hypoinsulinemic hypoglycemia and body hemihypertrophy
Research & Literature
03 Getting the Accurate Diagnosis 05 Tumor Screening & Long-Term Monitoring